Fujino, Toshio
Suda, Kenichi
Koga, Takamasa
Hamada, Akira
Ohara, Shuta
Chiba, Masato
Shimoji, Masaki
Takemoto, Toshiki
Soh, Junichi
Mitsudomi, Tetsuya
Funding for this research was provided by:
Japan Society for the Promotion of Science (19K16813 and 21K15580, 20H03773)
Article History
Received: 21 February 2022
Accepted: 1 June 2022
First Online: 11 June 2022
Declarations
:
: All animals were maintained in compliance with institutional guidelines and standards approved by the Institutional Animal Care and Use Committee of Kindai University (No. KDMS-29–006).
: Not applicable.
: Dr. Fujino has received research funding from Apollomics and Brighe Biotherapeutic and lecture fees from Novartis. Dr. Suda has received honoraria from Boehringer Ingelheim, Chugai and Taiho, has been on the advisory board of AstraZeneca, and has received research funding from Boehringer Ingelheim and Rain Therapeutics, outside of the submitted work. Dr. Koga has received research funding from Boehringer Ingelheim, outside of the submitted work. Dr. Hamada has received lecture fees from AstraZeneca and Chugai outside of the submitted work. Dr. Chiba has received honorarium from Ethicon, Olympus, B-Braun, and Covidien outside of the submitted work. Dr. Soh has received honoraria from Johnson and Johnson, Intutive, and AstraZeneca, outside the submitted work. Dr. Mitsudomi has received lecture fees from AstraZeneca, Boehringer Ingelheim, Chugai, and Pfizer and research funding from Astra Zeneca, Boehringer Ingelheim, and Chugai; in addition, he has been on the advisory board of Novartis and received lecture fees from Bristol-Myers Squibb, Eli Lilly, Merck Sharp and Dohme. Dr. Mitsudomi has also received research funding from Daiichi Sankyo, Taiho, and Ono Pharmaceutical, outside of the submitted work.